TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22901446

Group type: EXPERIMENTAL
Intervention: Obese group (BMI ≥ 30)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nonobese group (BMI < 30)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 300
Study: 20308489

Group type: EXPERIMENTAL
Intervention: Body Weight (BW) group with contrast dose of 360 mg I/kg BW
Number of subjects: 89

Group type: COMPARATOR
Intervention: Body Surface Area (BSA) group with contrast dose of 12,753 mg I/m(2) BSA
Number of subjects: 89
Study: 17369673

Group type: EXPERIMENTAL
Intervention: Various forms of cancer trials organized by the British Medical Research Council (MRC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery as the dominant form of therapy
Number of subjects: 0
Study: 15585553

Group type: EXPERIMENTAL
Intervention: Optimal band restriction
Number of subjects: 34

Group type: COMPARATOR
Intervention: Reduced band restriction
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LAGB subjects
Number of subjects: 34

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 34
Study: 12395978

Group type: COMPARATOR
Intervention: Diclofenac 75 mg alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nateglinide 120 mg alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Concomitant nateglinide 120 mg and diclofenac 75 mg
Number of subjects: 18
Study: 10048900

Group type: EXPERIMENTAL
Intervention: Low-dose nandrolone decanoate (65 mg/week)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-dose nandrolone decanoate (200 mg/week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (i.m.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nandrolone treatment (both doses)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate therapy (12-week open-label follow-up)
Number of subjects: 18
Study: 7762853

Group type: EXPERIMENTAL
Intervention: Mirfentanil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Butorphanol
Number of subjects: 18
Study: 2212180

Group type: EXPERIMENTAL
Intervention: Self-instructional guide about AIDS and its transmission with group instruction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-instructional guide about AIDS and its transmission without group instruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition (neither guide nor group instruction)
Number of subjects: 60
Study: 7039004

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 124
Study: 31599827

Group type: EXPERIMENTAL
Intervention: Self-discontinuation
Number of subjects: 157

Group type: COMPARATOR
Intervention: Office discontinuation
Number of subjects: 157
Study: 30339989

Group type: EXPERIMENTAL
Intervention: Targeting the Ultra-poor (TUP) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-participant households)
Number of subjects: 0
Study: 27338456

Group type: EXPERIMENTAL
Intervention: Folic acid 400 μg (two times/daily) for three months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Folic acid intervention
Number of subjects: 66
Study: 25042159

Group type: EXPERIMENTAL
Intervention: iPad use (investigational group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study: 22493925

Group type: EXPERIMENTAL
Intervention: Tuina treatment (local manipulations on breasts combined with acupoint manipulations)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (rooming-in conventional managements)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tuina treatment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 20565790

Group type: EXPERIMENTAL
Intervention: 10 sessions of acupuncture plus usual GP care
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual GP care alone
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis at 12 months
Number of subjects: 220
Study: 18202422

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (100 mg/m²) with carboplatin (AUC = 6 mg/mL x min)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Standard regimen of paclitaxel (225 mg/m²) and carboplatin (AUC = 6) every 3 weeks
Number of subjects: 444
Study: 15700191

Group type: EXPERIMENTAL
Intervention: IOP-lowering therapy
Number of subjects: 129

Group type: COMPARATOR
Intervention: No IOP-lowering therapy
Number of subjects: 129
Study: 12618969

Group type: EXPERIMENTAL
Intervention: Condylar positioning devices
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alternative method for intraoperative assessment of mandibular repositioning
Number of subjects: 30
Study: 10626564

Group type: EXPERIMENTAL
Intervention: Oestrogen therapy initiated at 12 years of age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oestrogen therapy initiated at 15 years of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 0
Study: 8529507

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glimepiride (in severe patients treated by large doses of glibenclamide)
Number of subjects: 0
Study: 1949925

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg i.v.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 7023863

Group type: EXPERIMENTAL
Intervention: Supervised three-month running program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 31
Study: 31026534

Group type: EXPERIMENTAL
Intervention: Levodopa therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levodopa therapy (ON-medication condition)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levodopa therapy (OFF-medication condition)
Number of subjects: 24
Study: 27734202

Group type: EXPERIMENTAL
Intervention: FLS training platform
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ED-FLS platform
Number of subjects: 39
Study: 26220734

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Serum amyloid A (SAA)
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Soluble tumor necrosis factor receptor‐2 (sTNFRII)
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Monokine induced by gamma interferon (CXCL9/MIG)
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Inflammation score combining CRP, SAA, sTNFRII, and CXCL9/MIG
Number of subjects: 1153
Study: 25428509

Group type: COMPARATOR
Intervention: Education-only
Number of subjects: 188

Group type: COMPARATOR
Intervention: Group-based support
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study: 21668788

Group type: EXPERIMENTAL
Intervention: Scleral-fixated posterior chamber intraocular lens
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Iris-fixated anterior chamber intraocular lens
Number of subjects: 49
Study: 19671303

Group type: EXPERIMENTAL
Intervention: TENS treatment at acupoints ST36 (Zusanli) and PC6 (Neiguan) twice a day for 2 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: TENS treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham TENS treatment
Number of subjects: 39
Study: 17332097

Group type: EXPERIMENTAL
Intervention: Computer-assisted cup positioning system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Freehand cup positioning
Number of subjects: 60
Study: 15777070

Group type: EXPERIMENTAL
Intervention: Vitamin E 1200 IU daily
Number of subjects: 0
Study: 9581727

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g three times daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 7994817

Group type: EXPERIMENTAL
Intervention: Renin inhibitor remikiren
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitor enalaprilat
Number of subjects: 36

Group type: COMPARATOR
Intervention: Combination of remikiren and enalaprilat
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 2662790

Group type: EXPERIMENTAL
Intervention: Percutaneous catheter drainage
Number of subjects: 50

Group type: COMPARATOR
Intervention: Repeat trial of conservative therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Therapeutic needle aspirations
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open surgical drainage
Number of subjects: 50
Study: 8956

Group type: EXPERIMENTAL
Intervention: Dibenzepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30875343

Group type: EXPERIMENTAL
Intervention: ECT plus 5 mg/d donepezil
Number of subjects: 0

Group type: COMPARATOR
Intervention: ECT with placebo
Number of subjects: 0
Study: 29169373

Group type: EXPERIMENTAL
Intervention: Morning dosing of hypertensive medication
Number of subjects: 21116

Group type: COMPARATOR
Intervention: Evening dosing of hypertensive medication
Number of subjects: 21116
Study: 26427805

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) - 1.1Gy+2Gy per day, 5 days/week for 4.5 weeks, total dose 68Gy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional fractionation (CF) - 2Gy per day, 5 days/week for 7 weeks, total dose 68Gy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 0
Study: 24127763

Group type: EXPERIMENTAL
Intervention: Case-Based Learning (CBL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lecture-Based Education (LBE)
Number of subjects: 40
Study: 21673197

Group type: EXPERIMENTAL
Intervention: Menstrual cup
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tampons
Number of subjects: 110
Study: 18422441

Group type: EXPERIMENTAL
Intervention: 1 g valacyclovir TID for 7 days
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 2 g valacyclovir TID for 7 days
Number of subjects: 87

Group type: COMPARATOR
Intervention: 800 mg acyclovir 5 times per day for 7 days (previous study)
Number of subjects: 87
Study: 16411525

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 20
Study: 12846625

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neuromuscular-blocking agent (NMB) with tracheal tube ventilation
Number of subjects: 40
Study: 10804381

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 0
Study: 8653145

Group type: EXPERIMENTAL
Intervention: Television viewing (EEtv)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Resting metabolic rate (RMR)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Self-selected television viewing duration
Number of subjects: 123
Study: 1506846

Group type: EXPERIMENTAL
Intervention: Tabular format
Number of subjects: 114

Group type: COMPARATOR
Intervention: Graphics format
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Gender (Men)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Gender (Women)
Number of subjects: 114
Study: 6492943

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure recordings
Number of subjects: 30
Study: 31868695

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation; 4 stimulations per day for 4 weeks.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham-device; 4 stimulations per day for 4 weeks.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation and Sham-device; measured with the 13C-octanoic acid breath test.
Number of subjects: 19
Study: 30206110

Group type: EXPERIMENTAL
Intervention: palbociclib plus fulvestrant
Number of subjects: 195

Group type: COMPARATOR
Intervention: placebo plus fulvestrant
Number of subjects: 195
Study: 26418414

Group type: EXPERIMENTAL
Intervention: CAPSULE (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: TABLET (diclofenac sodium enteric-coated tablet)
Number of subjects: 12
Study: 24831596

Group type: EXPERIMENTAL
Intervention: Flow diversion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional endovascular coiling therapy
Number of subjects: 0
Study: 22221615

Group type: EXPERIMENTAL
Intervention: PAB-F (pantoprazole 40mg-bid, amoxicillin 1g-bid, bismuth subcitrate 240mg-bid for 2 weeks, furazolidone 200mg-bid for the first week)
Number of subjects: 296

Group type: COMPARATOR
Intervention: PA-CT (pantoprazole 40mg-bid for 10 days, amoxicillin 1g-bid for the first 5 days, clarithromycin 500mg-bid plus tinidazole 500mg-bid for the second 5 days)
Number of subjects: 296
Study: 20460065

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (RSWT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50
Study: 17763897

Group type: COMPARATOR
Intervention: Conventional stripping (CON)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Invaginated stripping (INVAG)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 17590964

Group type: EXPERIMENTAL
Intervention: Music selected by the experimenter from the subject's preferred genre or artist (n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Specific song selected by the subject (n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No music (control group) (n = 30)
Number of subjects: 90
Study: 10851943

Group type: EXPERIMENTAL
Intervention: Screening for ovarian cancer
Number of subjects: 0
Study: 9358111

Group type: EXPERIMENTAL
Intervention: Topical oat colloidal grain suspension (0.007% and 0.7%)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Topical rice colloidal grain suspension (0.007% and 0.7%)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Radioallergosorbent tests (RAST)
Number of subjects: 65
Study: 8261678

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (2 micrograms postdialysis three times per week)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral calcitriol (2 micrograms postdialysis three times per week)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Both intravenous and oral calcitriol
Number of subjects: 11
Study: 3486840

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29967954

Group type: EXPERIMENTAL
Intervention: Prasugrel (20/3.75 mg, loading/maintenance dose) with aspirin (100 mg)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Clopidogrel (300/75 mg) with aspirin (100 mg)
Number of subjects: 742
Study: 27562352

Group type: EXPERIMENTAL
Intervention: Tea catechin beverage (570 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 16
Study: 24875045

Group type: EXPERIMENTAL
Intervention: 100% augmented feedback
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 50% augmented feedback
Number of subjects: 34

Group type: COMPARATOR
Intervention: 0% augmented feedback
Number of subjects: 34
Study: 22133704

Group type: EXPERIMENTAL
Intervention: Postoperative bulky dressing for 2 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Bandage removal at 48 to 72 hours with placement of an adhesive strip
Number of subjects: 94
Study: 20182703

Group type: EXPERIMENTAL
Intervention: tamsulosin, 0.4 mg/day for 4 weeks
Number of subjects: 92
Study: 17707382

Group type: EXPERIMENTAL
Intervention: P2RY12 haplotype H2
Number of subjects: 708

Group type: COMPARATOR
Intervention: Control group (matched white males free of vascular disease)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: P2RY12 variants or haplotype H2
Number of subjects: 708
Study: 16184478

Group type: EXPERIMENTAL
Intervention: Highest NAE quintile (most acidic)
Number of subjects: 27096

Group type: EXPERIMENTAL
Intervention: Higher NAE levels among men who smoked for more than 45 years
Number of subjects: 27096

Group type: COMPARATOR
Intervention: Lowest NAE quintile (least acidic)
Number of subjects: 27096
Study: 12357146

Group type: EXPERIMENTAL
Intervention: Goal-directed intraoperative fluid administration (protocol group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard intraoperative care (control group)
Number of subjects: 100
Study: 10479195

Group type: EXPERIMENTAL
Intervention: Olive oil-based intravenous lipid emulsion (ILE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Soybean oil-based emulsion
Number of subjects: 18
Study: 8562983

Group type: EXPERIMENTAL
Intervention: Nurse case manager
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional management by physicians
Number of subjects: 0
Study: 1912556

Group type: EXPERIMENTAL
Intervention: Self-administered IFN alpha‐2b, 3 million units subcutaneously thrice weekly for 1 year (n = 10)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Self-administered IFN alpha‐2b, 3 million units subcutaneously thrice weekly for 6 months (n = 6 after initial no-treatment)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no treatment) (n = 8)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IFN treatment for 1 year
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IFN treatment for 6 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Histologic scores after 12 months
Number of subjects: 18
Study: 7036336

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirenzepine (75 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31987371

Group type: EXPERIMENTAL
Intervention: AKT-inhibitors in combination with first-line chemotherapy
Number of subjects: 0
Study: 28425253

Group type: COMPARATOR
Intervention: B2-G haplotype
Number of subjects: 1927

Group type: COMPARATOR
Intervention: B2B2 genotype
Number of subjects: 1927

Group type: COMPARATOR
Intervention: B2B2 genotype in males
Number of subjects: 1927

Group type: COMPARATOR
Intervention: B2 allele
Number of subjects: 1927
Study: 26019464

Group type: EXPERIMENTAL
Intervention: Bio‐Three tablets (9 tablets/day) containing 2 mg of lactomin, 10 mg of Clostridium butyricum TO‐A, and 10 mg of Bacillus mesentericus TO‐A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo tablets (9 tablets/day)
Number of subjects: 60
Study: 23553051

Group type: EXPERIMENTAL
Intervention: Low-sugar jam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-sugar jam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-sugar jam with antioxidant
Number of subjects: 16
Study: 21760636

Group type: EXPERIMENTAL
Intervention: Weight stigmatizing video
Number of subjects: 73

Group type: COMPARATOR
Intervention: Neutral video
Number of subjects: 73
Study: 19430040

Group type: EXPERIMENTAL
Intervention: Combination of antioxidant Phenovin and immunomodulator Una de gato
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17380549

Group type: EXPERIMENTAL
Intervention: Warming group (conductive carbon polymer mattress used 2 hours before and after surgery)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Warming group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 15538131

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (800 to 1600 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: S-adenosyl-L-methionine
Number of subjects: 30
Study: 11418543

Group type: EXPERIMENTAL
Intervention: Direct physician order entry using the Medical Gopher system
Number of subjects: 11

Group type: COMPARATOR
Intervention: Traditional paper‐based ordering methods
Number of subjects: 11
Study: 9269759

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF; 5 microg/kg) administered intravenously 2 hours before endotoxin challenge
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF; 5 microg/kg) administered subcutaneously 24 hours before endotoxin challenge
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8329254

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.15 mg i.v. followed by buprenorphine 0.3 mg i.m. and then buprenorphine 0.4 mg sublingual
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Papaveretum 10 mg i.v. followed by papaveretum 20 mg i.m. and then buprenorphine 0.4 mg sublingual
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.15 mg i.v. followed by papaveretum 20 mg i.m. and then buprenorphine 0.4 mg sublingual
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Papaveretum 10 mg i.v. followed by buprenorphine 0.3 mg i.m. and then buprenorphine 0.4 mg sublingual
Number of subjects: 120
Study: 2883393

Group type: EXPERIMENTAL
Intervention: Ty21a attenuated Salmonella typhi oral vaccine in an enteric‐coated formulation
Number of subjects: 109000

Group type: COMPARATOR
Intervention: Ty21a vaccine in gelatin capsules with sodium bicarbonate
Number of subjects: 109000

Group type: EXPERIMENTAL
Intervention: Ty21a vaccine
Number of subjects: 109000
Study: 28880698

Group type: EXPERIMENTAL
Intervention: Skills TO Manage Pain (STOMP) intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study: 26438518

Group type: EXPERIMENTAL
Intervention: Milk powder supplementation with 300 mg calcium per day (Group A)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Milk powder supplementation with 600 mg calcium per day (Group B)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Milk powder supplementation with 900 mg calcium per day (Group C)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 210
Study: 25251201

Group type: EXPERIMENTAL
Intervention: Injectable, extended-release naltrexone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23063084

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g IV (GrAP)
Number of subjects: 310

Group type: COMPARATOR
Intervention: No antibiotic (GrAPn)
Number of subjects: 310
Study: 20173194

Group type: EXPERIMENTAL
Intervention: Implementation intention encoding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral practice
Number of subjects: 0